- Home
- RCS vs ANGO Comparison
RCS vs ANGO Comparison
Compare RCS & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | ANGO |
|---|---|---|
| Founded | 1994 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6M | 550.8M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | RCS | ANGO |
|---|---|---|
| Price | $6.24 | $13.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 141.1K | ★ 485.3K |
| Earning Date | 01-01-0001 | 01-07-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,718,000.00 |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $4.51 | $8.27 |
| 52 Week High | $6.31 | $13.99 |
Technical Indicators
Market Signals| Indicator | RCS | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 53.91 |
| Support Level | $6.00 | $13.12 |
| Resistance Level | $6.76 | $13.91 |
| Average True Range (ATR) | 0.17 | 0.39 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 24.05 | 16.49 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.